Activation of GPR119 by fatty acid agonists augments insulin release from clonal β-cells and isolated pancreatic islets and improves glucose tolerance in mice

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Abstract G-protein coupled receptor 119 (GPR119) is emerging as a potential target for the treatment of type 2 diabetes with beneficial effects on glucose homeostasis. This study assessed the insulin-secreting properties of various GPR119 agonists and the distribution of GPR119 in pancreatic islets. Endogenous ligands [oleoylethanolamide (OEA), palmitoylethanolamine (PEA)] and chemically synthetic analogues (AS-1269574, PSN-375963) were investigated in clonal BRIN-BD11 cells and mouse pancreatic islets. Secondary messenger assays such as intracellular Ca2+ and cAMP in response to agonists at normoglycaemic and hyperglycaemic conditions were assessed. Cytotoxicity was assessed by LDH release. AS-1269574 was the most potent and selective agonist tested in isolated islets, with an EC50 value of 9.7×10-7 mol/l, enhancing insulin release maximally by 63.2%. Stimulation was also observed with GPR119 ligands; OEA (3.0×10-6 mol/l; 37.5%), PSN-375963 (2.4×10-6 mol/l; 28.7%) and PEA (1.2×10-6 mol/l; 22.2%). Results were corroborated by studies using BRIN-BD11 cells, which revealed augmentation of intracellular Ca2+ and cAMP. Both OEA and AS-1269574 enhanced insulin release and improved glucose tolerance in-vivo in NIH Swiss mice. These results demonstrate the cellular localisation of GPR119 on islet cells (β and pancreatic polypeptide cells), its activation of the β-cell stimulus-secretion coupling pathway and glucose lowering effects in vivo.
LanguageEnglish
Pages453-464
JournalBiological Chemistry
Volume395
Issue number4
Early online date6 Dec 2013
DOIs
Publication statusPublished - 1 Apr 2014

Fingerprint

G-Protein-Coupled Receptors
Islets of Langerhans
Fatty Acids
Chemical activation
Insulin
Glucose
Pancreatic Polypeptide-Secreting Cells
Ligands
Pancreatic Polypeptide
Secretory Pathway
Cytotoxicity
Medical problems
Type 2 Diabetes Mellitus
Assays
Homeostasis
oleoylethanolamide
2-(2-(4-bromophenyl)-6-methylpyrimidin-4-yl)aminoethanol
PSN 375963

Cite this

@article{e54d5fc1aa604a85a458aacbf07e3752,
title = "Activation of GPR119 by fatty acid agonists augments insulin release from clonal β-cells and isolated pancreatic islets and improves glucose tolerance in mice",
abstract = "Abstract G-protein coupled receptor 119 (GPR119) is emerging as a potential target for the treatment of type 2 diabetes with beneficial effects on glucose homeostasis. This study assessed the insulin-secreting properties of various GPR119 agonists and the distribution of GPR119 in pancreatic islets. Endogenous ligands [oleoylethanolamide (OEA), palmitoylethanolamine (PEA)] and chemically synthetic analogues (AS-1269574, PSN-375963) were investigated in clonal BRIN-BD11 cells and mouse pancreatic islets. Secondary messenger assays such as intracellular Ca2+ and cAMP in response to agonists at normoglycaemic and hyperglycaemic conditions were assessed. Cytotoxicity was assessed by LDH release. AS-1269574 was the most potent and selective agonist tested in isolated islets, with an EC50 value of 9.7×10-7 mol/l, enhancing insulin release maximally by 63.2{\%}. Stimulation was also observed with GPR119 ligands; OEA (3.0×10-6 mol/l; 37.5{\%}), PSN-375963 (2.4×10-6 mol/l; 28.7{\%}) and PEA (1.2×10-6 mol/l; 22.2{\%}). Results were corroborated by studies using BRIN-BD11 cells, which revealed augmentation of intracellular Ca2+ and cAMP. Both OEA and AS-1269574 enhanced insulin release and improved glucose tolerance in-vivo in NIH Swiss mice. These results demonstrate the cellular localisation of GPR119 on islet cells (β and pancreatic polypeptide cells), its activation of the β-cell stimulus-secretion coupling pathway and glucose lowering effects in vivo.",
author = "BM Moran and Yasser Abdel-Wahab and Peter Flatt and Aine McKillop",
year = "2014",
month = "4",
day = "1",
doi = "10.1515/hsz-2013-0255",
language = "English",
volume = "395",
pages = "453--464",
journal = "Biological Chemistry",
issn = "1431-6730",
number = "4",

}

TY - JOUR

T1 - Activation of GPR119 by fatty acid agonists augments insulin release from clonal β-cells and isolated pancreatic islets and improves glucose tolerance in mice

AU - Moran, BM

AU - Abdel-Wahab, Yasser

AU - Flatt, Peter

AU - McKillop, Aine

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Abstract G-protein coupled receptor 119 (GPR119) is emerging as a potential target for the treatment of type 2 diabetes with beneficial effects on glucose homeostasis. This study assessed the insulin-secreting properties of various GPR119 agonists and the distribution of GPR119 in pancreatic islets. Endogenous ligands [oleoylethanolamide (OEA), palmitoylethanolamine (PEA)] and chemically synthetic analogues (AS-1269574, PSN-375963) were investigated in clonal BRIN-BD11 cells and mouse pancreatic islets. Secondary messenger assays such as intracellular Ca2+ and cAMP in response to agonists at normoglycaemic and hyperglycaemic conditions were assessed. Cytotoxicity was assessed by LDH release. AS-1269574 was the most potent and selective agonist tested in isolated islets, with an EC50 value of 9.7×10-7 mol/l, enhancing insulin release maximally by 63.2%. Stimulation was also observed with GPR119 ligands; OEA (3.0×10-6 mol/l; 37.5%), PSN-375963 (2.4×10-6 mol/l; 28.7%) and PEA (1.2×10-6 mol/l; 22.2%). Results were corroborated by studies using BRIN-BD11 cells, which revealed augmentation of intracellular Ca2+ and cAMP. Both OEA and AS-1269574 enhanced insulin release and improved glucose tolerance in-vivo in NIH Swiss mice. These results demonstrate the cellular localisation of GPR119 on islet cells (β and pancreatic polypeptide cells), its activation of the β-cell stimulus-secretion coupling pathway and glucose lowering effects in vivo.

AB - Abstract G-protein coupled receptor 119 (GPR119) is emerging as a potential target for the treatment of type 2 diabetes with beneficial effects on glucose homeostasis. This study assessed the insulin-secreting properties of various GPR119 agonists and the distribution of GPR119 in pancreatic islets. Endogenous ligands [oleoylethanolamide (OEA), palmitoylethanolamine (PEA)] and chemically synthetic analogues (AS-1269574, PSN-375963) were investigated in clonal BRIN-BD11 cells and mouse pancreatic islets. Secondary messenger assays such as intracellular Ca2+ and cAMP in response to agonists at normoglycaemic and hyperglycaemic conditions were assessed. Cytotoxicity was assessed by LDH release. AS-1269574 was the most potent and selective agonist tested in isolated islets, with an EC50 value of 9.7×10-7 mol/l, enhancing insulin release maximally by 63.2%. Stimulation was also observed with GPR119 ligands; OEA (3.0×10-6 mol/l; 37.5%), PSN-375963 (2.4×10-6 mol/l; 28.7%) and PEA (1.2×10-6 mol/l; 22.2%). Results were corroborated by studies using BRIN-BD11 cells, which revealed augmentation of intracellular Ca2+ and cAMP. Both OEA and AS-1269574 enhanced insulin release and improved glucose tolerance in-vivo in NIH Swiss mice. These results demonstrate the cellular localisation of GPR119 on islet cells (β and pancreatic polypeptide cells), its activation of the β-cell stimulus-secretion coupling pathway and glucose lowering effects in vivo.

U2 - 10.1515/hsz-2013-0255

DO - 10.1515/hsz-2013-0255

M3 - Article

VL - 395

SP - 453

EP - 464

JO - Biological Chemistry

T2 - Biological Chemistry

JF - Biological Chemistry

SN - 1431-6730

IS - 4

ER -